Locus Cell Co., Ltd. announced that it has recruited Dr. Campana, who is best known for his CAR-T expertise, as its Chief Scientific Advisor. With the help of Locus team and clinicians in Taiwan, together they will establish Taiwan as a global centre for Car-T research and development.

Dr. Campana is the inventor of Novartis' CD19 CAR-T assets, which received drug approval in Taiwan in October 2021 for a range of conditions including blood cancers and lymphomas, and patients can expect to receive this emerging cancer treatment in Taiwan, with a single treatment to achieve disease relief.

Dr. Campana visited Taiwan earlier this month and was invited by NTU Hospital and Locus Cell to give a lecture at NTU Children's Hospital, attended by distinguished guests who are medical influencers in Taiwan's healthcare community.

Dr. Campana said that the overall environment for cell therapy in Taiwan has potential and that he is interested in and excited about the future of innovative digital applications with CAR-T.

Currently, there are 6 CAR-T products in the world. In the future, Locus Cell will introduce Dr. Campana's PEBL proprietary technology platform to move towards the goal of allogeneic cell therapy, and will also introduce a one-stop facility and plan a multi-station system to make Taiwan a global R&D centre for CAR-T with the help of clinicians and major R&D teams in Taiwan.